Eli Lilly Expands LillyDirect With Walmart Partnership for Zepbound Pickups

Eli Lilly is expanding access to its obesity treatment Zepbound through a new retail collaboration with Walmart, marking the first in-store pickup option for its direct-to-consumer platform, LillyDirect.

Under the partnership, Walmart’s nearly 4,600 pharmacies across the U.S. will serve as the first in-store pickup locations for LillyDirect’s self-pay, single-dose Zepbound vials. This offering, set to launch by mid-November, represents a significant expansion of convenience and choice for consumers seeking authentic Lilly medications without relying on insurance.

Zepbound vials will be available in all approved strengths, with the lowest dose priced at $349 per month for self-pay customers. Patients with a valid, on-label prescription can purchase directly through LillyDirect and choose between free home delivery or pickup at their local Walmart Pharmacy.

Customers initiating or continuing therapy can have prescriptions routed electronically to LillyDirect Self Pay Pharmacy Solutions through their healthcare provider’s EHR system, making access more seamless than ever.

Eli Lilly launched LillyDirect in January 2024 to simplify access to its portfolio of medicines for obesity, diabetes, and migraine. The platform integrates telehealth services, pharmacy delivery, and digital tools to support patients through every step of treatment.

The introduction of self-pay, single-dose Zepbound vials earlier this year was part of Lilly’s effort to meet rising demand and improve affordability. Now, with Walmart’s addition, the company aims to further extend patient reach and convenience.

LillyDirect also collaborates with several virtual care providers for Zepbound prescriptions, including 9amHealth, Form Health, and knownwell, as well as partners like Ro, LifeMD, Teladoc Health, and Amazon Pharmacy, to provide broader access to lower-cost medication options.